Highlights on selpercatinib in RET fusion-positive NSCLC: The LIBRETTO-431 study

ESMO 2023 Lung Cancer - Chapter 2 Highlights – PAPILLON, MARIPOSA, MARIPOSA-2, LIBRETTO-431Подробнее

Selpercatinib Induced Durable Efficacy in RET Fusion-Positive NSCLCПодробнее

Highlights on selpercatinib in RET-mutant medullary thyroid cancer: The LIBRETTO-531 studyПодробнее

The impact of selpercatinib in patients with RET fusion-positive NSCLCПодробнее

Intracranial activity of selpercatinib in RET fusion positive NSCLCПодробнее

FDA approval of selpercatinib for RET fusion positive NSCLC and thyroid cancersПодробнее

RET fusion-positive mNSCLC: selpercatinib and pralsetinibПодробнее

RET Fusion Treatment: Selpercatinib - Targeted Therapies in Lung Cancer 2023Подробнее

Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid c...Подробнее

Selpercatinib benefit, with or without pembro, in first-line advanced RET fusion-positive NSCLCПодробнее

[lung] Effect of selpercatinib for RET-positive patientsПодробнее

Selpercatinib Data Underscore Value of Precision Medicine in RET-Driven Lung CancerПодробнее

[lung] Selpercatinib is also effective against brain metastasis.Подробнее

Treatments for RET+ NSCLC: Selpercatinib vs. Pralsetinib - 2022 Program: Targeted Therapies ForumПодробнее

Selpercatinib and Pralsetinib in RET + Disease - Lung Cancer Video LibraryПодробнее

Selpercatinib in RET-altered Thyroid Cancers with Dr. Lori WirthПодробнее

[lung] Selpercatinib (LOXO-292) being given to the lung cancer patient for the first timeПодробнее

Emerging Agents and Combinations to Treat RET Fusion-Positive Lung CancersПодробнее